S

SCI Pharmtech Inc
TWSE:4119

Watchlist Manager
SCI Pharmtech Inc
TWSE:4119
Watchlist
Price: 83.1 TWD 0.48%
Market Cap: 9.9B TWD
SCI Pharmtech Inc
/
Balance Sheet
/
Cash & Cash Equivalents

SCI Pharmtech Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SCI Pharmtech Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
SCI Pharmtech Inc
TWSE:4119
Cash & Cash Equivalents
NT$582.4m
CAGR 3-Years
21%
CAGR 5-Years
1%
CAGR 10-Years
4%
Y
YungShin Global Holding Corp
TWSE:3705
Cash & Cash Equivalents
NT$1.7B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
5%
Formosa Laboratories Inc
TWSE:4746
Cash & Cash Equivalents
NT$1.4B
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
13%
ScinoPharm Taiwan Ltd
TWSE:1789
Cash & Cash Equivalents
NT$4.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
8%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Cash & Cash Equivalents
NT$6B
CAGR 3-Years
55%
CAGR 5-Years
36%
CAGR 10-Years
19%
Standard Chem & Pharm Co Ltd
TWSE:1720
Cash & Cash Equivalents
NT$1.5B
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
11%

SCI Pharmtech Inc
Glance View

Market Cap
9.9B TWD
Industry
Pharmaceuticals

SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others

Intrinsic Value
58.86 TWD
Overvaluation 29%
Intrinsic Value
Price
S
What is Intrinsic Value?

See Also

What is SCI Pharmtech Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
582.4m TWD

Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Cash & Cash Equivalents amounts to 582.4m TWD.

What is SCI Pharmtech Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
4%

Over the last year, the Cash & Cash Equivalents growth was -38%. The average annual Cash & Cash Equivalents growth rates for SCI Pharmtech Inc have been 21% over the past three years , 1% over the past five years , and 4% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.